Navigation Links
Medpace Director of Clinical Pharmacology, Jim Wei, MD, PhD, Embarks on a Regulatory Policy Speaking Tour in China in May
Date:5/5/2008

CINCINNATI, May 5 /PRNewswire/ -- Medpace, a leading global full-service contract research organization, announced that Jim Wei, MD, PhD, Medpace Director of Clinical Pharmacology, will address three international conferences in China in May. He will speak at the Impact China IV Conference in Beijing, at the International Workshop on Mass Spectrometry and New Drug Development in Hangzhou, and at the International Society for the Study of Xenobiotics in Shanghai.

At the Impact China IV Conference in Beijing, China on 4-6 May, Dr. Wei will speak on "The Role of Foreign Data and FDA Requirements." In his presentation he will discuss how both pre-clinical and clinical data from foreign countries has increased in Investigational New Drug Application (IND), New Drug Application (NDA), and Biologic License Application (BLA) submissions in the US.

Dr. Wei will talk about "Current FDA Policy and Opportunities for the Chinese Pharmaceutical Industry" at the International Workshop on Mass Spectrometry and New Drug Development in Hangzhou, China on 8-10 May. In his presentation Dr. Wei will discuss regulatory policies that would help Chinese generic suppliers and the opportunities for botanical drug products in the US market.

At the Second Asian Pacific Regional Meeting of the International Society for The Study of Xenobiotics, held in Shanghai, China on 11-13 May, Dr. Wei will speak on the "Current US FDA Recommendations on Drug Interaction Studies and Challenges to the Pharmaceutical Industry." In this presentation he will reveal the challenges to the pharmaceutical industry -- the requirement of the knowledge level of drug metabolism and drug interactions, optimal design of in vitro and in vivo studies, and integrated analyses to assess the risk/benefit ratio of new drugs for potential harmful drug interactions.

Dr. Wei joined Medpace in November 2007 with extensive experience in the clinical trial regulatory aspects of early phase studies. He came to Medpace from the FDA where he served as a Senior Reviewer in the Office of Clinical Pharmacology and was also heavily involved in reviewing INDs and NDAs for the Division of Metabolism and Endocrinology Products.

ABOUT MEDPACE

Medpace is a leading global full-service contract research organization led by top therapeutic and regulatory experts who are driven to further the advancement of pharmaceutical agents for use in cardiology, metabolism, and oncology. Medpace has assembled the industry's most experienced and therapeutically focused team to execute at every level of the company's operations, providing complete and seamless drug development services.

Through specialized regulatory expertise and therapeutically focused clinical operations, Medpace creates strategic partnerships with pharmaceutical and biotechnology companies to provide the most efficient and cost-effective path to drug development -- from program planning and execution to product approval.

With more than 700 employees and clinical trial experience in over 40 countries, Medpace has the global reach and capability to conduct studies and navigate regulatory requirements worldwide within the core therapeutic areas of cardiology, metabolism, and oncology.

Medpace provides centralized image management and reading from Imagepace, centralized laboratory and therapeutically specialized testing from Medpace Reference Laboratories, and Phase I / IIa research services from Medpace Clinical Pharmacology.
Visit the Medpace website at http://www.medpace.com

Contact: John Wynne, 513-579-9911, x2407

j.wynne@medpace.com


'/>"/>
SOURCE Medpace, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Related medicine news :

1. Facet Solutions, Inc. Appoints Industry Veteran to Board of Directors
2. Phyhealth Appoints Gerald H. Priceman as Medical Director
3. Halleland Health Consulting Hires New Director of Lifescience Business Development Peter T. Bianco
4. NightHawk Radiology Holdings, Inc. Announces Appointment of David Engert to the Board of Directors
5. Seattle-Based Marsha Rivkin Center for Ovarian Cancer Research Appoints Nancy Sclater, Executive Director
6. Allen Kukovich, Director, Governors Southwest PA Office, Joins Call for Quality Affordable Health Insurance
7. Mentice, Inc. Expands Its North American Sales and Clinical Presence With the Hiring of Jeff Sirek as Director of Educational Sales-East and Sue Landsman as Clinical Applications Manager for the Americas.
8. Executive Director of cbm US congratulates UN on Malaria Campaign
9. Lotus Pharmaceuticals, Inc. Announces Resignation of Director Mel Rothberg
10. US Oncology Welcomes New Director of Federal Government Relations
11. Steris Corporation Announces the Appointment of Two New Directors
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/28/2017)... IL (PRWEB) , ... February 28, 2017 , ... Today, ... ten years of saving lives by empowering young women to live proactively at a ... 1 in 75 will develop ovarian cancer. Prevention and early detection can save lives-but ...
(Date:2/28/2017)... ... February 28, 2017 , ... The ... America for the scientific development, healthcare training and clinical application of medical infrared ... Session on September 16-17 in Greenville, SC at the Bon Secours St. Francis ...
(Date:2/28/2017)... CA (PRWEB) , ... February 28, 2017 , ... ... Health Coach Institute (HCI) announced a new partnership through which HCI students, ... their coaching curriculum and practices. The partnership also enables the HCI community to ...
(Date:2/28/2017)... ... February 28, 2017 , ... In 2014, Harvard researchers published a report ... from prostate cancer, the researchers found that men who had undergone a vasectomy were ... prostate cancer. Although the increased risks are small, they seem to be contradicted by ...
(Date:2/28/2017)... ... ... Las Vegas Skin and Cancer Clinic (LVSCC) is proud to announce the ... pm PST. For more than six decades, LVSCC has provided the Las Vegas community ... been renovated to provide medical and cosmetic dermatological products and services. Patients at the ...
Breaking Medicine News(10 mins):
(Date:2/28/2017)... Calif. , Feb. 27, 2017  Titan ... therapeutics for the treatment of select chronic diseases ... today announced that the U.S. Food & Drug ... the ropinirole implant Investigational New Drug Application (IND) ... of the clinical study pending submission of the ...
(Date:2/28/2017)... and SAN FRANCISCO , February 27, 2017 ... Se D BioMedical ... of biotechnology assets   LOI contemplates capital infusion ... for building shareholder value   Amarantus names four new appointees ... Amarantus   SeD Biomedical Inc. (SeD ...
(Date:2/28/2017)... Feb. 27, 2017 Pulmonary drug delivery market ... from USD 36.10 billion in 2016, at a CAGR ... pulmonary route as an alternate route of drug delivery, ... increasing incidence of respiratory diseases such as COPD, asthma, ... growth during the forecast period. However, emerging markets and ...
Breaking Medicine Technology: